Sign in
Taking people in United StatesNo phase

Predicting Blood Sugar From Glucose Sensor and Daily Habit Data in Type 2 Diabetes

Builds models predicting blood sugar from sensor and habit data in type 2 diabetes.

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Registry title
Multimodal Glucose Prediction in Type 2 Diabetes
Status
Recruiting
People taking part
36 people, planned
Started
7 Oct 2026
Expected to end
26 Feb 2027
Type of study
Observational
Treatments tested
  • Digital Health Data Collection System
Record updated
8 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who use a CGM (continuous glucose monitor) and an Android phone. It will study glucose prediction using CGM, food, medication and activity data.

Age
18 to 75 years old
Sex
All sexes can join
Disease stage
Type 2 diabetes managed by a primary care doctor or endocrinologist at Johns Hopkins Medicine. CGM Time in Range must be under 70% in the 14 days before enrollment.
Earlier treatment
Must already use a Dexcom G7 or FreeStyle Libre 3 CGM, with 2 weeks of use and at least 50% wear time before the study. Must not use an insulin pump.
Biomarker or test result
CGM time below range must not be above 4% in the 14 days before enrollment.

Main reasons for not taking part

  • Pregnant
  • Uses an insulin pump (automated insulin delivery system)
  • Other forms of diabetes, such as type 1, LADA, MODY or gestational diabetes
  • Uses an Apple iOS phone, not an Android phone
  • Hospitalized for diabetic ketoacidosis or a severe low blood sugar episode in the previous 6 months

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • 18-75 years old
  • Registered patient under Johns Hopkins Medicine (JHM)
  • Type 2 Diabetes diagnosis
  • Diabetes managed by a primary care physician or endocrinologist at JHM
  • Android Smartphone user
  • Must have a Dexcom G7 or FreeStyle Libre 3 CGM and using a mobile app to access their CGM data (G7 or Libre 3 apps)
  • 2 weeks of usage (with at least 50% wear time) prior to study participation required
  • CGM Time in Range of <70% in 14 days prior to enrollment
  • Must be able to read, understand, and communicate in English
  • Must not have hearing or vision impairments
  • Willingness to Download the Welldoc app
  • Agree to wear a SAMSUNG Galaxy Watch at least 12 hours per day
  • Download SAMSUNG Health (Non-SAMSUNG Phone user)
  • Download Google Health Connect
  • Use CGM at least 80% of the time
  • Take a photo of all meals

Who cannot take part

  • CGM time-below-range > 4% (i.e. hypoglycemia) in the 14 days prior to enrollment
  • Hospitalization for Diabetic Ketoacidosis (DKA) or severe hypoglycemic episode within the previous 6 months
  • Has hearing or vision impairment
  • Diagnosed with other forms of diabetes (e.g. Type 1 Diabetes, Latent Autoimmune Diabetes in Adults (LADA), Maturity-Onset Diabetes of the Young (MODY), or Gestational diabetes)
  • Pregnant
  • Non-English speaker
  • Use of an insulin pump (i.e. automated insulin delivery system)
  • Non-Android smartphone user (i.e., Apple iOS)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Johns Hopkins MedicineBaltimore, United StatesContact: Nestoras Mathioudakis, MD, MHSTaking people

About the trial

What the trial wants to find out

The primary objective of this research, funded by Samsung Strategic Alliance for Research and Technology, is to develop multi-modal foundation models that integrate Continuous Glucose Monitoring (CGM) data with patient behavior data (food intake, medication, and physical activity) to improve real-time glucose prediction and personalized diabetes management for patients with Type 2 diabetes (T2D), delivered via mobile apps and digital health tools.

The group in the trial

  • Adults With Type 2 Diabetes Using CGM

    Adults with type 2 diabetes receiving care through Johns Hopkins Medicine will participate in a single site observational cohort study. Participants will continue usual diabetes care and will not receive a treatment intervention from the study team. Participants will contribute CGM, smartwatch, app-based behavioral, and electronic medical record data for development and validation of glucose prediction models. Study-generated messages and summary reports will be reviewed by the study team and will not be delivered to participants.

    Treatment: Digital Health Data Collection System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
CGM- and Behavior-based Large Health Model for Just-in-time Diabetes Management
Plain-language title
Predicting Blood Sugar From Glucose Sensor and Daily Habit Data in Type 2 DiabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07633171, who can take part
Record updated
8 October 2026